These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6099543)

  • 1. [Analysis of results of monochemotherapy of ovarian cancer with special reference to long-term survival].
    Sablińska B; Cześnin K; Ploch E
    Nowotwory; 1984; 34(3):229-35. PubMed ID: 6099543
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intratumor chemotherapy of patients with cancer of the ovaries].
    Vinokurov VL; Mitrokhina MV
    Vopr Onkol; 1983; 29(8):58-61. PubMed ID: 6310891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy in the treatment of cancer of the ovary.
    Smith JP; Rutledge F
    Am J Obstet Gynecol; 1970 Jul; 107(5):691-703. PubMed ID: 4316665
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide.
    Young RC; Canellos GP; Chabner BA; Schein PS; Hubbard SP; DeVita VT
    Gynecol Oncol; 1974 Dec; 2(4):489-97. PubMed ID: 4376998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic ovarian cancer.
    Smith JP; Rutledge FN
    Clin Obstet Gynecol; 1973 Jun; 16(2):286-97. PubMed ID: 4351522
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemotherapy of ovarian cancer. New approaches to treatment.
    Smith JP; Rutledge F; Wharton JT
    Cancer; 1972 Dec; 30(6):1565-71. PubMed ID: 4345098
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy for advanced ovarian cancer.
    Rutledge F; Burns BC
    Am J Obstet Gynecol; 1966 Nov; 96(6):761-72. PubMed ID: 4162786
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant therapy for advanced ovarian malignancy.
    Decker DG; Mussey E; Malkasian GD; Johnson CE
    Am J Obstet Gynecol; 1967 Jan; 97(2):171-80. PubMed ID: 4289460
    [No Abstract]   [Full Text] [Related]  

  • 9. Factors influencing ovarian cancer survival after chemotherapy.
    Webb MJ; Malkasian GD; Jorgensen EO
    Obstet Gynecol; 1974 Oct; 44(4):564-70. PubMed ID: 4413425
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I and II evaluation of cytembena in disseminated epithelial ovarian cancers and sarcomas.
    Baker LH; Samson MK; Izbicki RM
    Cancer Treat Rep; 1976 Sep; 60(9):1389-91. PubMed ID: 189923
    [No Abstract]   [Full Text] [Related]  

  • 11. Integrated therapy in the treatment of ovarian cancer with surgery, radiation and chemotherapy.
    Speckhard ME; Hurley JD; Fetherston WC; Grueninger AJ
    Oncology; 1972; 26(2):297-309. PubMed ID: 4340440
    [No Abstract]   [Full Text] [Related]  

  • 12. [Combined chemotherapy of ovarian cancer with special reference to carboquone].
    Sugimori H; Kidera Y; Matsuyama T
    Gan To Kagaku Ryoho; 1982 Jan; 9(1):66-71. PubMed ID: 6307172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tissue reaction in ovarian carcinoma after cyclophosphamide (Endoxan) therapy].
    Engeler V; Hanski W
    Pathol Microbiol (Basel); 1969; 33(3):153-60. PubMed ID: 5350583
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resection.
    Barlow JJ; Lele SB; Emrich LJ
    Am J Obstet Gynecol; 1985 Jun; 152(3):310-4. PubMed ID: 2988337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immediate results of sarcolysine therapy of patients with malignant tumors of the ovaries].
    Semenovskiĭ AV
    Vopr Onkol; 1983; 29(3):54-7. PubMed ID: 6836988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer.
    Conte PF; Sertoli MR; Bruzzone M; Rubagotti A; Rosso R; Bentivoglio G; Conio A; Pescetto G
    Gynecol Oncol; 1985 Mar; 20(3):290-7. PubMed ID: 2982705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin and cyclophosphamide, alternated with bleomycin and mitomycin C as a second-line regimen in advanced ovarian carcinoma resistant to cisplatin-based chemotherapy.
    Benedetti Panici P; Scambia G; Greggi S; Salerno G; Cento R; Mancuso S
    Oncology; 1990; 47(4):296-8. PubMed ID: 1694980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy of ovarian cancer with melphalan.
    Rutledge F
    Clin Obstet Gynecol; 1968 Jun; 11(2):354-66. PubMed ID: 4971815
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cyclophosphamide as adjuvant treatment of the advanced ovarian carcinoma].
    Malkasian GD; Mussey E; Decker DG; Johnson CE
    Gynecol Prat; 1967; 18(6):545-53. PubMed ID: 4316435
    [No Abstract]   [Full Text] [Related]  

  • 20. Natural killer cell activity and progression-free survival in ovarian cancer.
    Garzetti GG; Cignitti M; Ciavattini A; Fabris N; Romanini C
    Gynecol Obstet Invest; 1993; 35(2):118-20. PubMed ID: 8383627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.